Cost effectiveness of a protocol using palivizumab in preterm infants

The main objective was to evaluate the cost-effectiveness of protocol use of palivizumab in premature established by consensus in our Hospital comparing it based on the recommendations of various Scientific Societies. As a secondary objective risk factors and severity of hospitalized patients attend...

Full description

Saved in:
Bibliographic Details
Published in:Farmacia hospitalaria 2017-03, Vol.41 (2), p.169-186
Main Authors: Hernández-Gago, Yolanda, Lombardero-Pin, Marina, Cruz, Casilda Ortega de la, Maciuniak, Pablo A., Pino, Alicia Díez del
Format: Article
Language:English
Subjects:
Cost-effectiveness
Edad gestacional
Eficiencia
Gestational age
Neonate
Neonato
Palivizumab
Premature
Prematuro
Respiratory syncytial virus
Virus sincitial respiratorio
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The main objective was to evaluate the cost-effectiveness of protocol use of palivizumab in premature established by consensus in our Hospital comparing it based on the recommendations of various Scientific Societies. As a secondary objective risk factors and severity of hospitalized patients attending the established protocol in our Hospital were analyzed. The study period was 4 seasons with the expanded protocol (retrospective data) versus 2 with restricted or agreed protocol (prospective data). The perspective of the study was the Health System, including the costs of hospitalization and palivizumab our center. The calculation of the effectiveness was determined with the admission rate of premature patients stratified by weeks of gestational age
ISSN:1130-6343
2171-8695
DOI:10.7399/fh.2017.41.2.10565